Greetings,

As an investor, we want to share with you the latest information regarding a forward-thinking pharmaceutical company, Provectus Pharmaceuticals, Inc. (OTCBB: PVCT).

Additional Data on Provectus's PV-10 for Metastatic Melanoma Presented at Prominent Melanoma Conferences

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announced that data and preliminary Phase 3 study design features on PV-10 for metastatic melanoma were presented at two separate conferences.

Data was presented by two of Provectus's Principal Investigators for the Phase 2 melanoma study, Dr. Sanjiv Agarwala, M.D., Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA, and by Professor Merrick Ross, M.D., of the MD Anderson Cancer Center in Houston, Texas. Dr. Agarwala delivered a presentation entitled "Chemoablation of Metastatic Melanoma with Intralesional PV-10," at the 7th EADO (European Association of Dermato-Oncology) Conference in Nantes, France, and Dr. Ross's presentation was entitled "Intralesional Therapy for Systemic Disease: Implications for Success and Failure," at the HemOnc Today Conference in New York City.

In his presentation, Dr. Agarwala reviewed Phase 2 data on PV-10 and outlined primary design parameters for the Company's anticipated Phase 3 randomized controlled trial of PV-10, noting that the design is based on guidance obtained in meetings with the U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA). Dr. Agarwala's presentation may be viewed at: http://www.pvct.com/publications/Chemoablation_of_MM_with_PV-10-EADO-2011.pdf.

The complete press release is available at http://www.pvct.com/pressrelease.html?article=20110629 on the Provectus website.

Research reports from the following industry leading organizations are available by request:

· Rodman & Renshaw

· Maxim Group

· Stonegate Securities

· Agora Financial

Additionally, you may subscribe to their newsletter at https://www.pvct.com/contactform.html and receive the latest company news and press releases via e-mail. Provectus news items are also available via their RSS news feed www.pvct.com/pvctnews.rss.

Thank you for your time.

Address:

Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931

+1 (866) 594.5999

www.pvct.com

DISCLAIMER: This is a paid advertisement provided to our subscribers. Although we have sent you this email, Financial Market Advisor does not endorse this product or company nor is it responsible for the content of this ad. Furthermore, we make no guarantee or warranty about what is advertised above, and have not independently reviewed the information provided within this advertisement.

In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that Financial Market Advisor/Zack's Vertical Reach Media are receiving a fee of $6,600 in cash, from Provectus Pharmaceuticals, Inc. as compensation for the distribution of this advertisement. Financial Market Advisor has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment.

Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the National Association of Securities Dealers (the "NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at http://www.sec.gov/consumer/cyberfr.htm, as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.

Advertiser:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 3793